Author

G. L. Semenza

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:cell-cell communication· 1 Research Focus:development & morphogenesis· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

D. M. Gilkes· 1 shared D. Samanta· 1 shared D. Z. Chen· 1 shared G. K. Kumar· 1 shared G. Yuan· 1 shared J. A. Garcia· 1 shared J. Nanduri· 1 shared J. O. Liu· 1 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

D. M. Gilkes

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Homeostatic responses to hypoxia by the carotid body and adrenal medulla are based on mutual antagonism between HIF-1α and HIF-2α

G. Yuan, Y.-J. Peng, V. D. Reddy, V. Makarenko, J. Nanduri, S. A. Khan, J. A. Garcia, G. K. Kumar, G. L. Semenza, N. R. Prabhakar

This study shows that HIF-1α and HIF-2α antagonism in the carotid body and adrenal medulla regulates redox balance and hypoxia responses, maintaining blood pressure and respiration.

bioRxiv · Jul 11, 2022 · PreprintPhysiology

Enrichment of breast cancer stem cells following cytotoxic chemotherapy is mediated by hypoxia-inducible factors

D. Samanta, D. M. Gilkes, L. Xiang, P. Chaturvedi, G. L. Semenza

This study shows that cytotoxic chemotherapy in TNBC increases BCSCs via HIFs, leading to relapse, and that HIF inhibitors can block this effect.

bioRxiv · Jun 27, 2022 · PreprintCancer Biology

Daily administration of low-dose daunorubicin or doxorubicin inhibits hypoxia-inducible factor 1 and tumor vascularization

Y. Yang, D. Z. Chen, S. Rey, J. O. Liu, G. L. Semenza

The paper identifies anthracyclines as HIF-1 inhibitors that reduce tumor vascularization by blocking HIF-1 target genes and angiogenesis.

bioRxiv · Jun 15, 2022 · PreprintCancer Biology